Landmark PROTEUS Trial Results Released: Herbert Wertheim Cancer Institute Experts Discuss Impact on High-Risk Prostate Cancer
The landmark PROTEUS trial evaluated intensified perioperative therapy in high-risk localized prostate cancer. Herbert Wertheim Cancer Institute experts say findings may reshape future treatment pathways.
The highly anticipated results of the PROTEUS trial have generated significant interest among prostate cancer specialists worldwide. The landmark study evaluated intensified perioperative therapy in men with high-risk localized prostate cancer undergoing radical prostatectomy.
Physicians from Herbert Wertheim Cancer Institute who participated in the study believe the findings may reshape future treatment pathways for select patients with aggressive prostate cancer. The results provide important insight into the role of neoadjuvant and perioperative systemic therapy in improving long-term oncologic outcomes.
Experts note that delaying or reducing the need for additional treatments while maintaining durable cancer control remains one of the most meaningful goals for patients diagnosed with high-risk disease. Ongoing analyses and long-term follow-up are expected to further define how intensified perioperative therapy may be incorporated into routine clinical practice.
